Three Rivers Joins CTA San Francisco Life Sciences
TORONTO, ON, November 4, 2016 - Three Rivers joins the Canadian Technology Accelerator (CTA) program in San Francisco as one of six Canadian high potential growth life sciences companies selected in a competitive process by the Trade Canadian Service (TCS).
CTA San Francisco Life Sciences is a four month program run by the Canadian Consulate in San Francisco that seeks to help life science companies by connecting Canadian CEOs and entrepreneurs with US customers and global strategic partners.
“This opportunity will allow our company to build relationships with venture capital investors on the West Coast,” says Eric Caron, CEO of Three Rivers.
During the CTA program in San Francisco and Silicon Valley, Three Rivers will be provided with introductions to Fortune 500 companies and investors enabling strategic partnerships and venture financing. The program will also include presentations and mentoring sessions by domain experts, potential customers and investors.
The TCS established the CTA program in 2009 to help create liaisons between Canadian companies and key resources in the San Francisco region. Additionally, the Canadian Consulate has partnered with SPIRE Bioventures, to provide comprehensive support to qualified Canadian companies as part of the CTA Life Sciences Program.
CTA runs from November 7th, 2016 to February 29th, 2017.
About Three Rivers:
The company was founded in 2013 to develop and commercialize multi-sensor medical devices for interventional cardiologists. Three Rivers’ innovative medical devices provide real-time critical data for heart diagnosis and therapy to improve patient outcomes while reducing healthcare costs with heart diseases.